Olverembatinib
Aliases
AMG 103, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, blincyto, Blincyto (4 other aliases)
15 clinical trials
2 abstracts
33 indications
Indication
Chronic Myeloid LeukemiaIndication
Burkitt LymphomaIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
Follicular LymphomaIndication
Grade 2 Follicular LymphomaIndication
Grade 3 Follicular LymphomaIndication
Recurrent Grade 3b Follicular LymphomaIndication
Gray-Zone LymphomaIndication
Mantle Cell LymphomaIndication
Marginal Zone LymphomaIndication
Mediastinal LymphomaIndication
Non-Hodgkin LymphomaIndication
Small Lymphocytic LymphomaIndication
Burkitt lymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Refractory Gray-Zone LymphomaIndication
Refractory Mediastinal LymphomaIndication
Ph+ ALLIndication
Refractory Non-Hodgkin LymphomaIndication
Hematopoietic/Lymphoid CancerIndication
Richter TransformationIndication
Acute lymphoblastic leukemia, adult typeIndication
Philadelphia Chromosome PositiveIndication
CD19-positiveIndication
Acute Lymphoblastic LeukemiaIndication
Acute lymphoblastic leukemiaIndication
RecurrentIndication
AdultIndication
B-precursor acute lymphoblastic leukemiaAbstract
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, The Affliated Cancer Hospital of Zhengzhou University,
Clinical trial
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Single-arm, Single-center Clinical TrialStatus: Recruiting, Estimated PCD: 2024-10-25
Clinical trial
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Blinatumomab in the Treatment of Adult de Novo Philadelphia Chromosome Positive Acute Lymphoid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationStatus: Terminated, Estimated PCD: 2022-02-11
Clinical trial
A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)Status: Completed, Estimated PCD: 2021-08-15
Clinical trial
A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With DLBCLStatus: Completed, Estimated PCD: 2021-04-07
Clinical trial
The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)Status: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2030-12-01
Clinical trial
An Open Label, Phase I/II Study of Venetoclax in Addition to Blinatumomab Immunotherapy in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)Status: Recruiting, Estimated PCD: 2025-06-30
Abstract
Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).Org: Fudan University Shanghai Cancer Center, Henan Cancer Hospital, Union Hospital Medical College Huazhong University of Science and Technology, Guangdong Provincial People's Hospital, Chinese People’s Liberation Army General Hospital,
Clinical trial
Efficacy and Safety of Molecular Targeted Therapy Combined With Chemotherapy and Sequential CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-06-01